Asthma was not discovered in a single dramatic moment. The word itself first appeared in Homer’s Iliad nearly three thousand years ago, meaning a short, gasping breath, and physicians in ancient Greece were already writing about it as a medical condition by the fifth century BCE. But recognizing that someone struggles to breathe is different from understanding why, and the story of asthma is really a story of successive layers of insight, each generation peeling back a little more of the mystery. From Hippocrates debating whether asthma was a disease or merely a symptom, to twenty-first-century biologic drugs that shut down specific inflammatory molecules, the condition has been continuously rediscovered.
The Word Before the Disease
The term “asthma” comes from the Greek verb aazein, meaning to exhale with an open mouth or to pant. It shows up in the Iliad purely as a description of physical distress on the battlefield, not as a medical diagnosis. The earliest text in which the word appears as a medical term is the Corpus Hippocraticum, the body of writings attributed to Hippocrates and his school between roughly 460 and 360 BCE. Even then, scholars are not sure whether Hippocrates meant asthma as a standalone illness or was simply using the word to describe labored breathing as a symptom of other conditions.1PubMed. Bronchial asthma in the medical literature of Greek antiquity That ambiguity would linger for centuries.
The distinction matters because the ancient world recognized many causes of difficult breathing: heart disease, lung infections, heavy exertion. Grouping all panting under one label meant that early “asthma” was not what a modern physician would call asthma. It was a catchall complaint, and separating it from other forms of breathlessness took a very long time.
Aretaeus and the First Clinical Picture
The person usually credited with providing the first recognizable clinical description of asthma is Aretaeus of Cappadocia, a Greek physician who practiced in Rome during the first or second century CE. Aretaeus described episodic attacks of breathlessness, the patient’s distress, and the way symptoms flared and receded, producing a picture that modern physicians can read and say, “Yes, that’s asthma.”2American Journal of Respiratory and Critical Care Medicine. Aretaeus of Cappadocia and the first clinical description of asthma His writing moved the concept beyond a vague label and toward something a doctor could diagnose at the bedside.
Still, Aretaeus had no tools beyond his own senses and no theory of inflammation. He observed the pattern of the illness without being able to explain what caused it, a limitation that would persist through the medieval period and well into the Renaissance.
Maimonides and Medieval Practical Advice
In the twelfth century, the philosopher and physician Moses Maimonides wrote a dedicated Treatise on Asthma. It was one of the first monographs to focus on the condition specifically rather than mentioning it in passing. Maimonides organized the accumulated knowledge of Greek and Arab physicians before him and laid out a logical system for prevention, diagnosis, and treatment. His advice was largely dietary and environmental: avoid certain foods, keep the air clean, get rest.3PubMed Central. Moses Maimonides’ treatise on asthma
By today’s standards much of the advice seems quaint, but the underlying instinct was sound. Maimonides noticed that environmental triggers mattered, that some patients worsened in dusty or polluted conditions, and that lifestyle changes could reduce attacks. The idea that asthma had external triggers, not just internal imbalances, was quietly radical for its time.
The First Full-Length Book on Asthma
The English physician Sir John Floyer published A Treatise of the Asthma in 1698, and it stands as the first comprehensive monograph on the disease in Western medicine. Floyer was himself asthmatic, so his clinical descriptions drew on decades of personal suffering in addition to his medical practice. He carefully distinguished asthma from other forms of shortness of breath, making the case that it was its own disease entity rather than a symptom shared across many conditions.4PubMed Central. Sir John Floyer’s A Treatise of the Asthma (1698)
Floyer’s contribution was in some ways the logical endpoint of a question that had been open since Hippocrates: is asthma a disease or a symptom? With Floyer, the answer was firmly “a disease,” and that framing stuck. Physicians after him could debate what caused asthma without needing to argue over whether it existed as a separate condition.
Listening to the Lungs
For most of history, physicians had to rely on what the patient reported and what they could see. That changed in 1816 when René Laënnec invented the stethoscope. For the first time, doctors could hear the wheezes, crackles, and silences inside the chest in real time. The expiratory wheezes of asthma became a hallmark finding, one that did not show up on an X-ray or in a blood test but was immediately apparent through a stethoscope pressed to the back.5JAMA. Lung Sounds Through the Ages: From Hippocrates to Laënnec to Osier
Auscultation, the practice of listening through the stethoscope, gave clinicians a way to objectively confirm an asthma attack and distinguish it from heart failure or a blocked airway. It turned diagnosis from pure storytelling into something partially measurable. Around the same time, microscopists studying the sputum of asthmatic patients began finding distinctive structures: Charcot-Leyden crystals and Curschmann spirals, both indicators of the eosinophilic inflammation now understood to be central to many cases of asthma.6PMC. Charcot-Leyden crystals and Curschmann spirals in asthmatic sputum These discoveries hinted that something immunological was going on inside the airways, long before anyone had the vocabulary to say so.
Pollen, Allergies, and a Kite With a Sticky Tail
One of the more charming episodes in asthma history involves the British physician Charles Harrison Blackley, who in 1873 became the first person to formally identify pollen as the cause of hay fever and what he called “hay asthma.” Blackley himself suffered from seasonal asthma, and his experiments were hands-on in the most literal sense. He flew a kite with a sticky surface attached to its tail to collect pollen grains at altitude, then counted them. He also performed the first skin prick test on his own arm, deliberately exposing himself to pollen to document the allergic reaction.7European Respiratory Journal. From pollen count to pollen potency: the molecular era of aerobiology
Blackley’s work was foundational because it established a concrete, external cause for at least some asthma. Before him, theories ranged from nervous imbalances to spiritual temperament. After him, the idea that specific substances in the environment could provoke attacks became increasingly hard to ignore, opening the door to the entire field of allergy science.
Victorian Smoking Cures and Other Dead Ends
Not every chapter in asthma history pointed in the right direction. Throughout the nineteenth century, one of the most popular treatments was inhaling the smoke of stramonium, a plant in the nightshade family also known as jimsonweed or thorn apple. Physicians called it “divine stramonium” and prescribed asthma cigarettes containing the dried leaves.8PubMed Central. “Divine stramonium”: the rise and fall of smoking for asthma The plant contains anticholinergic compounds that do relax airway smooth muscle, so patients felt temporary relief. But the delivery method, literally smoking, was damaging in its own right, and the dose was impossible to control.
Asthma cigarettes remained widely available into the early twentieth century, sometimes sold over the counter. Their eventual decline came not from a single study but from the gradual rise of better treatments and, eventually, the broader recognition that inhaling smoke of any kind is harmful to diseased lungs. The episode is a useful reminder that treatments can “work” in the short term while making the underlying condition worse.
Adrenaline, Inhalers, and the Modern Pharmacy
The pharmacological treatment of asthma took its first real leap around 1900, when physicians discovered that subcutaneous injections of adrenaline could abort a severe asthma attack. This was dramatic and effective, but adrenaline stimulates the entire body, not just the airways, so side effects like racing heartbeat and tremors were common. Over the following decades, chemists worked to create synthetic relatives of adrenaline that were more selective to the lungs. The discovery of isoprenaline in 1940 was the first major step toward targeted bronchodilation.9PubMed. Beta-adrenoceptor agonists and asthma–100 years of development
The next revolution was in how drugs were delivered. In 1956, Riker Laboratories introduced the first pressurized metered-dose inhaler, or MDI. It was the first truly portable and convenient device that could get medication directly into the lungs, and it gained widespread acceptance quickly.10PubMed Central. The History of Therapeutic Aerosols: A Chronological Review The early inhalers delivered non-selective drugs like adrenaline and isoprenaline. But a surge of asthma deaths in the 1960s, partly linked to overuse of these potent bronchodilators, pushed the field to develop safer alternatives. Salbutamol, a selective short-acting bronchodilator with fewer cardiac side effects, eventually replaced the older drugs. Around the same time, the first inhaled corticosteroid, beclomethasone, became available, marking the beginning of a shift from purely relieving spasm to actually treating the inflammation underneath.11PubMed Central. A brief history of inhaled asthma therapy over the last fifty years
The Inflammation Revelation
For most of the twentieth century, asthma was thought of primarily as a disease of twitchy airways: smooth muscle around the bronchial tubes would contract, narrowing the passage and making it hard to breathe. Treatment logically focused on relaxing that muscle. Beta-agonist inhalers did exactly that, and they worked fast. But they did not address whatever was irritating the airways in the first place, and patients who relied on them without additional treatment often got worse over time.12PubMed. Time for a paradigm shift in asthma treatment: from relieving bronchospasm to controlling systemic inflammation
The turning point came when researchers demonstrated that chronic airway inflammation, not just spasm, was the core problem in most asthma patients. This insight emerged from multiple directions at once. Biopsy studies showed swollen, inflamed airway tissue even in patients who felt fine between attacks. Laboratory work revealed that chemical mediators called leukotrienes, released from immune cells in the lungs, directly contract bronchial smooth muscle and amplify inflammation.13PubMed. Discovery of leukotrienes and development of antileukotriene agents The identification of leukotrienes eventually led to a new class of drugs, the leukotriene receptor antagonists like montelukast, that could reduce inflammation through a completely different pathway than corticosteroids.14PubMed. Leukotrienes: One step in our understanding of asthma
Meanwhile, the discovery of Immunoglobulin E (IgE) in the mid-1960s filled in another piece of the puzzle. IgE turned out to be the antibody responsible for the immediate allergic response, the molecular go-between that connects an inhaled allergen like pollen to the cascade of mast-cell activation and histamine release that triggers an asthma attack.15PubMed Central. The discovery of IgE 50 years later For the first time, the chain from allergen exposure to wheezing could be traced link by link.
Global Guidelines and the Recognition of a Public Health Problem
By the 1980s, asthma prevalence was climbing in many industrialized countries, and governments began to take it seriously as a public health issue. The first national asthma guidelines appeared in the mid-1980s.16PubMed. GINA guidelines on asthma and beyond In the early 1990s, the Global Initiative for Asthma (GINA) was established as a collaboration between the U.S. National Heart, Lung, and Blood Institute and the World Health Organization. GINA has published yearly updates to its global strategy ever since, reviewing the latest evidence and issuing recommendations that shape asthma care worldwide.17PubMed Central. Update on Asthma Management Guidelines
The creation of GINA reflected a shift in thinking. Asthma was no longer simply a clinical problem for individual doctors and patients; it was a condition affecting hundreds of millions of people globally, with enormous variation in access to diagnosis and treatment. Standardized guidelines helped reduce some of that variation, although gaps between high-income and low-income countries remain stark.
Biologics and the Precision Medicine Era
The most recent chapter in asthma’s history began with biologic therapies, drugs engineered to target specific molecules in the inflammatory cascade. The first to arrive was omalizumab, an anti-IgE antibody that blocks the allergic sensitization pathway. It has been improving outcomes for patients with allergic asthma for over a decade. Since then, three anti-IL-5 biologics and one anti-IL-4 receptor biologic have entered the market, all aimed at patients whose asthma is driven by a pattern of immune activity known as type 2 inflammation. In clinical use, these targeted therapies reduce flare-ups, improve lung function, cut down on oral steroid use, and improve quality of life for patients who were previously difficult to treat.18PubMed Central. Role of Biologics in Asthma
Biologics represent the practical payoff of decades of immunological detective work. Without the discovery of IgE, the identification of leukotrienes, and the recognition that asthma is fundamentally an inflammatory disease, these drugs would not exist. They also highlight how far the definition of “asthma” has evolved: it is no longer a single disease but a syndrome with several distinct subtypes, each driven by different immune mechanisms and each potentially requiring a different treatment approach.
Parallel Traditions Outside Western Medicine
The Western narrative from Hippocrates to biologics is the most documented one, but it is not the only one. Traditional Chinese medicine has its own long history of treating asthma-like symptoms with herbal formulas, operating from a completely independent system of theory, diagnosis, and treatment. A number of anti-asthma herbal combinations are recorded in classical TCM textbooks and remain in clinical use in parts of Asia, though only a handful have been studied with the kind of controlled trials that Western medicine demands.19PubMed Central. Efficacy and mechanisms of action of traditional Chinese medicines for treating asthma and allergy
Ayurvedic medicine in India and traditional practices in other cultures also addressed breathing difficulties long before the Greek tradition codified them. These traditions remind us that struggling to breathe is a universal human experience, and that every medical culture has tried to explain and treat it. Some of those traditional remedies contain compounds that modern pharmacology has found genuinely active; others remain untested. The overlap between ancient herbal approaches and modern drug targets is an active area of research, though it has produced more promising leads than proven therapies so far.
Why Asthma Keeps Being Rediscovered
One of the recurring themes in this history is that each era’s understanding of asthma was partly right and partly incomplete. Hippocrates was right that the condition involved labored breathing but could not say why. Floyer was right that it was a distinct disease but blamed it on nervous causes. Victorian doctors were right that inhaled substances could help but chose a delivery method that did harm. Twentieth-century physicians were right about bronchospasm but underestimated inflammation. Even the current biologic therapies work brilliantly for some patients and not at all for others whose asthma follows a non-type-2 inflammatory pattern that researchers are still working to understand.
Asthma was not discovered once. It has been discovered over and over, each time with greater clarity but never with completeness. The condition that Homer’s warriors panted through on the plains of Troy is the same condition that sends people to emergency rooms today, and scientists are still arguing over exactly what it is, how many subtypes it includes, and why its prevalence has risen so sharply in recent decades. That ongoing argument is itself the latest chapter in a history that stretches back nearly thirty centuries.